VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.

	Dec '19	Dec '20	Dec '21	Dec '22
revenue				27.34M -
cost of revenue
gross profit				27.34M -
selling and marketing expenses
general and administrative expenses	8.23M -	14.02M 70.28%	35.81M 155.42%	33.91M 5.29%
selling general and administrative expenses	8.23M -	14.02M 70.28%	35.81M 155.42%	33.91M 5.29%
research and development expenses	15.98M -	43.03M 169.31%	50.18M 16.60%	73.95M 47.38%
other expenses	102K -	207K 102.94%	729K 252.17%
cost and expenses	24.32M -	57.26M 135.50%	86.72M 51.44%	107.86M 24.39%
operating expenses	24.32M -	57.26M 135.50%	86.72M 51.44%	107.86M 24.39%
interest expense	50K -	554K 1,008%	36K 93.50%	3.16M 8,688.89%
ebitda	-24.15M -	-57.55M 138.34%	-86.41M 50.14%	-79.85M 7.60%
operating income	-24.32M -	-57.26M 135.50%	-86.72M 51.44%	-80.52M 7.14%
depreciation and amortization	167K -	-293K 275.45%	303K 203.41%	676K 123.10%
total other income expenses net	834K -	-2.68M 421.58%	-229K 91.46%	-13.10M 5,622.27%
income before tax	-23.48M -	-59.94M 155.28%	-86.94M 45.05%	-93.63M 7.69%
income tax expense	50K -	554K 1,008%	64K 88.45%	107K 67.19%
net income	-23.53M -	-60.50M 157.09%	-87.01M 43.82%	-93.73M 7.73%
weighted average shs out	23.35M -	9.60M 58.89%	26.96M 180.81%	44.13M 63.69%
weighted average shs out dil	23.35M -	9.60M 58.89%	26.96M 180.81%	44.13M 63.69%
eps	-1.01 -	-6.30 523.76%	-3.23 48.73%	-2.12 34.37%
epsdiluted	-1.01 -	-6.30 523.76%	-3.23 48.73%	-2.12 34.37%

NASDAQ:VECT

VectivBio

Last Close

16.85

07/07 19:59

Market Cap

1.06B

Beta: 0.05

Volume Today

127.65K

Avg: 38.14K

PE Ratio

−7.94

PFCF: −18.81

Preview